Effects of Ligands on Human Hair Follicles Grafted Onto SCID Mice

H

Hordinsky, Maria K., MD

Status and phase

Completed
Phase 1

Conditions

Alopecia

Treatments

Drug: FK506, GP11046, GP11511

Study type

Interventional

Identifiers

NCT00177099
0306M49486

Details and patient eligibility

About

The purpose of this study is to determine if immunophilin ligands may have the potential to reverse hair loss.

Full description

Preliminary experiments in C57BL/6J mice showed that immunophilin ligand FK506 and its non-immunosuppressive analogs, GP11046 and GP11511 were capable of promoting telogen to anagen transition. Since GP11046 and GP11511 possess the neurotrophic properties of FK506 without its immunosuppressant capability, the neural action of these immunophilin ligands may play an important role in the hair cycle. This finding has significant clinical implications in that immunophilin ligands may have the potential to reverse alopecia. To further investigate this possibility we propose to explore the response of transplanted miniaturized scalp hair follicles to topically applied immunophilin ligands.

Sex

Male

Ages

18 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Healthy men ages 18-65 with Hamilton type IV or V alopecia

Exclusion criteria

Individuals who do not meet the inclusion criteria.

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Factorial Assignment

Masking

None (Open label)

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems